Category: Biotech

June 6, 2022

After nearly eight years, Yumanity’s time as an independent company appears close to an end. The biotech was established in late 2014 — the creation of Tony Coles, Susan Lindquist and Ken Rhodes, each well-known in the pharmaceutical industry for […]

June 6, 2022

Athersys’s research efforts are centered around a cell therapy platform it has been studying across a range of conditions, including stroke, respiratory distress and heart attack. In stroke, Athersys is working with Japan’s Healios, which tested Athersys’ cell therapy as […]

May 25, 2022

Established in 2006, Genocea originally focused on vaccines. It went public in 2014 and at one point saw its shares soar above $150. But in 2017, just as the company was poised to begin a Phase 3 trial of an […]

May 24, 2022

BridgeBio Pharma is digging in for a prolonged bear market. Since suffering a phase 3 flop late last year, the biotech has taken a series of steps to extend its cash runway, reflecting its CEO’s belief that markets could “stay […]

May 23, 2022

Holding company Innoviva is acquiring late-stage antibiotic biotech Entasis Therapeutics, a 2015 AstraZeneca spin-out that just posted phase 3 results worthy of an FDA filing last year. Innoviva already owns about 60% of Entasis’ outstanding shares. Under the new definitive […]

May 19, 2022

A common infection, RSV results in only mild, cold-like symptoms in most people. Yet the disease causes 58,000 hospitalizations a year in children under 5 and 177,000 in the elderly. After decades of disappointment, vaccine makers may finally be close […]

May 9, 2022

ALSA Ventures, a London based European biotech investment firm, and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, have entered a collaboration agreement to help develop and manufacture biologics and small molecule drug candidates […]

May 5, 2022

Plunging valuations may be forcing biotechs to lay off staff and strip back their pipelines, but Big Pharma doesn’t think the price tags on offer are sufficiently tempting to justify a shopping trip quite yet. Judging by first-quarter earnings calls […]

May 5, 2022

The approval of Enhertu as a second-line option further establishes the drug’s growing role in breast cancer, where it’s quickly becoming a go-to treatment for the roughly 15% of patients with HER2-positive disease. First conditionally approved for third-line use in […]

May 4, 2022

Swiss biotechs saw record-breaking revenue and R&D investment in 2021, which the industry hopes will lead people to look beyond homegrown giants like Roche and Novartis. The new findings, outlined by the Swiss Biotech Association in its latest annual report […]

May 2, 2022

In the midst of new emerging therapy projects under development, the progress of innovative manufacturing technologies is also growing. One of the newest emerging platforms for biologics manufacturing is the plant made pharmaceutical platform (PMP). PMP has come on-stage recently […]

April 25, 2022

The results didn’t add up. BridgeBio Pharma, a young biotech trying to bring its first big drug to market, followed the blueprint of one of the world’s largest pharmaceutical companies. It made a medicine meant to work like the one […]